Humasis Co

Humasis Co Debt/Market Cap

The Debt to Market Capitalization Ratio of Humasis Co (205470.KQ) as of Nov 10, 2026 is 0.39 %. In the previous year, Debt to Market Capitalization Ratio was 2.46 % — a change of -83.99% (lower).

Debt/Market Cap

0.39 %

YoY

-83.99%

Last updated:

Debt to Market Capitalization Ratio of Humasis Co is 2025 0.39 % . Debt to Market Capitalization Ratio of Humasis Co was 2024 2.46 % . It decreases by -83.99% lower compared to the previous year.

The Humasis Co Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
12.03 KRW
Jan 1, 2019
8.50 KRW
Jan 1, 2020
13.85 KRW
Jan 1, 2021
2.62 KRW
Jan 1, 2022
2.50 KRW
Jan 1, 2023
0.14 KRW
Jan 1, 2024
2.46 KRW
Jan 1, 2025
0.39 KRW
The Humasis Co Debt/Market Cap history
YEARDebt/Market CapYoY
0.39 %-83.99%
2.46 %+1,709.41%
0.14 %-94.55%
2.50 %-4.79%
2.62 %-81.07%
13.85 %+63.03%
8.50 %-29.36%
12.03 %+12.33%
10.71 %+646.48%
1.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Debt to Market Capitalization Ratio of Humasis Co is 0.39 % in 2025.

Debt to Market Capitalization Ratio of Humasis Co changed from 2.46 % to 0.39 %, representing a -83.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Humasis Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Humasis Co

All Key Metrics — Humasis Co